Implantica conducts innovative eHealth workshop
Comunicato Precedente
Comunicato Successivo
"Implantica's expert team held a very productive eHealth usability workshop on our eHealth platform. With Implantica's new platform, it will be possible to change advanced treatment on distance, which will bring a total landmark in the development of new smart implanted eHealth-based medical treatments and thereby save costs for society. I would like to take this chance to thank all participants for a constructive 3 days," said Peter Forsell, CEO of Implantica.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
The information was sent for publication, through the agency of the contact person set out above, on February 11, 2022 at 08:30 a.m. CET.
About Implantica
Implantica is a medtech company dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-conducts-innovative-ehealth-workshop,c3504457
The following files are available for download:
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




